HCA FY2025 Q4 IMPROVING

HCA Healthcare, Inc. 실적 발표

Jan 27, 2026 · 05:00 ET Frank MorganMike MarksSam Hazen

Buzzberg 분석

2026 EBITDA guidance reflects $600M-$900M exchange headwind

HCA reported solid Q4 2025 results with 6.7% revenue growth, 11% adjusted EBITDA growth, and strong cash flow. Management provided FY2026 guidance that includes $600-$900M headwind from exchange subsidies and $250-$450M decline in supplemental payments, partially offset by $400M in resiliency savings. They maintained a constructive tone on long-term demand and margins, while increasing capex to $5-$5.5B. Q4 same-facility admissions +2.4%, equivalent admissions +2.5%, inline with 2-3% growth target.

Buzzberg 분석 2026 EBITDA guidance reflects $600M-$900M exchange headwind HCA reported solid Q4 2025 results with 6.7% revenue growth, 11% adjusted EBITDA growth, and strong cash flow. Management provided FY2026 guidance that includes $600-$900M headwind from exchange subsidies and $250-$450M decline in supplemental payments, partially offset by $400M in resiliency savings. They maintained a constructive tone on long-term demand and margins, while increasing capex to $5-$5.5B. Q4 same-facility admissions +2.4%, equivalent admissions +2.5%, inline with 2-3% growth target. 전체 분석 보기분석 접기

FY2025 adjusted EBITDA +12.1%, margin improved 90 bps; cash flow from operations $12.6B (+20% YoY).
FY2026 revenue guide $76.5-80B, EPS $29.10-31.50, capex $5-5.5B; margin expected slightly above 20%.
Exchange subsidy expiration and administrative reforms expected to reduce EBITDA by $600-900M.

Revenue $19.513B +2% QoQ

EPS $8.01 +15% QoQ

Gross margin 41.9% reported

Op margin 16.29% reported

이번 분기에 달라진 점

Guidance

2026 EBITDA guidance reflects $600M-$900M exchange headwind

Guidance · revenue to $78.25B

Cost Efficiency

Resiliency program to offset $400M of exchange impact

Q4 same-facility admissions +2.4%, equivalent admissions +2.5%, inline with 2-3% growth target.

Medicaid

Texas supplemental payment pause contributes to EBITDA decline

FY2025 adjusted EBITDA +12.1%, margin improved 90 bps; cash flow from operations $12.6B (+20% YoY).

AI investments across clinical, operational, and administrative domains

Management is investing heavily in AI across administrative, operational, and clinical domains, with the goal of driving efficiencies, improving patient care, and creating long-term value. They are implementing AI in revenue cycle, supply chain, and clinical decision support…

AI, 자본지출 및 수요 분석

플랫폼 및 수익화

수요

수주 및 전환

Exchange volume modeled to decline 15-20% in 2026. Management expressed confidence in their ability to navigate policy headwinds and execute on strategic initiatives, citing a strong balance sheet, robust resiliency programs, and a clear technology roadmap.

자본지출

투자 및 생산능력

Capital expenditures are expected to increase to $5 billion to $5.5 billion in 2026, funded by strong cash flow, to support organic growth, including high-acuity programs, new access points, and inpatient capacity.

톤 · Confident

Management expressed confidence in their ability to navigate policy headwinds and execute on strategic initiatives, citing a strong balance sheet, robust resiliency programs, and a clear technology roadmap.

향후 가이던스

ImprovingGuidance · revenue to $78.25B · was RAISED last Q

향후 가이던스
지표	기간	범위	중간값	상태
Capex	FY2026	$5B–$5.5B	$5.25B	INITIATED
EPS	FY2026	$29.10–$31.50	$30.30	INITIATED
Revenue	FY2026	$76.5B–$80B	$78.25B	INITIATED

가이던스 신뢰도

1 / 1달성 또는 상회

가이던스 신뢰도
제시 시점	지표	목표 기간	가이던스	실제	결과
FY2025 Q3	Capex	FY2025	$5B	$4.9B	Met / beat